Stocktoria
Samsung Biologics Co.,Ltd. 207940.KS
KR · Korea Exchange · XKRX · stock · Healthcare · website
Samsung Biologics Co.,Ltd. statistics & valuation
Market cap$63.42T
P / E35.5×
P / S13.9×
P / B8.5×
P / FCF82.1×
Net margin39.2%
Return on equity23.9%
FCF margin17.0%
Multiples are price-derived and refreshed daily; everything else is from filings.
P / E vs its own history
Samsung Biologics Co.,Ltd. trades at about 52.2× earnings — below its 10-year norm (10-year range 65.5×–109.2×, median 107.2×).
52.2×
109.2×
Shaded band = 10-year range (65.5×–109.2×); dot = today's 52.2×.
Historical P/E = month-end price near each fiscal year-end ÷ that year's EPS. A read on whether the stock is cheap or dear relative to how it has typically been valued — not a forecast.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Gross margin | 55.2% | 48.9% | 48.8% | 48.9% |
| Operating margin | 45.4% | 37.8% | 30.1% | 32.8% |
| Net margin | 39.2% | 31.0% | 23.2% | 26.6% |
| FCF margin | 17.0% | 8.1% | 15.2% | -1.9% |
| Return on assets | 16.1% | 6.2% | 5.3% | 4.8% |
| Return on equity | 23.9% | 9.9% | 8.7% | 8.9% |
| Debt / equity | 0.08× | 0.09× | 0.02× | 0.11× |
| Current ratio | 1.74 | 1.43 | 1.33 | 1.54 |
Source: company filings via Yahoo Finance · KR · as of 2025-12-31. Figures in KRW; non-US fundamentals are aggregated by Yahoo (shorter history); facts plus Stocktoria's own computed scores — not investment advice.